Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures

• Published in: NeuroImage clinical Vol. 18; pp. 86 - 96
• Main Authors: Simó, M., Gurtubay-Antolin, A., Vaquero, L., Bruna, J., Rodríguez-Fornells, A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.01.2018; Elsevier
• Subjects: Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Brain - physiopathology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - physiopathology; Carcinoma, Non-Small-Cell Lung - psychology; Chemobrain; Cognition - physiology; Cognition Disorders - chemically induced; Cognition Disorders - physiopathology; Cognition Disorders - psychology; Cognitive impairment; Electroencephalography; Error-related negativity (ERN); Event-related potentials-ERP; Evoked Potentials - physiology; Female; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - physiopathology; Lung Neoplasms - psychology; Male; Middle Aged; Performance monitoring; Regular; Error-related negativity (ERN); Event-related potentials-ERP; Chemobrain; Performance monitoring; Lung cancer; Cognitive impairment
• ISSN: 2213-1582; 2213-1582
• DOI: 10.1016/j.nicl.2017.12.032

No previous event-related potentials (ERPs) study has explored the error-related negativity (ERN) - an ERP component indexing performance monitoring - associated to cancer and chemotherapy-induced cognitive impairment in a lung cancer population. The aim of this study was to examine differences in performance monitoring in a small-cell lung cancer group (SCLC, C+) 1-month following chemotherapy and two control groups: a non-small cell lung cancer patient group (NSCLC, C−) prior to chemotherapy and a healthy control group (HC). Seventeen SCLC (C+) underwent a neuropsychological assessment and an ERP study using a flanker and a stop-signal paradigm. This group was compared to fifteen age-, gender- and education-matched NSCLC (C−) and eighteen HC. Between 20 and 30% of patients in both lung cancer groups (C+ and C−) met criteria for cognitive impairment. Concerning ERPs, lung cancer patients showed lower overall hit rate and a severe ERN amplitude reduction compared to HC. Lung cancer patients exhibited an abnormal pattern of performance monitoring thus suggesting that chemotherapy and especially cancer itself, may contribute to cognitive deterioration. ERN appeared as an objective laboratory tool sensitive to cognitive dysfunction in cancer population. •This is the first study to explore error-related negativity in lung cancer patients.•Lung cancer patients showed a severe ERN amplitude reduction.•ERN resulted a potential biomarker of cognitive impairment in lung cancer population.